< The 2014 All-America Research TeamTimothy AndersonSanford C. Bernstein & Co.First-place appearances: 4
Total appearances: 11
Team debut: 2003Holding on to second place on this lineup is Sanford C. Bernstein & Co.’s Timothy Anderson. The San Francisco–based analyst “is very competent and provides detailed research and global coverage,” in the words of one money manager. For his part, Anderson predicts that U.S. major pharmaceuticals names will perform in line with the broad market going into 2015. Year to date through mid-September, the group rose 15 percent, besting the wider market by 7.7 percentage points. “While some companies are making progress, others continue to have difficulty,” he notes, “and average valuations are about in line with the broader market.” The researcher’s top stock pick going forward is Indianapolis–based Eli Lilly and Co., whose brands include Cymbalta and Prozac for the treatment of depression, as well as erectile dysfunction therapy Cialis. “Despite the nearer-term impact of the patent cliff on Lilly’s financials, it has been one of the best long-term growth rates among peer companies in the big pharma sector,” says Anderson. “This is partly driven by its pipeline of late-stage products in development.”